申请人:Thuring Johannes Wilhelmus John F.
公开号:US20110269748A1
公开(公告)日:2011-11-03
This invention concerns the use of a compound of formula (I)
a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein
Z is hydrogen, halo, C
1-6
alkyl, Het
1
, HO—C
1-6
alkyl-, cyano-C
1-6
alkyl-, amino-C(═O)—C
1-6
alkyl-, formylamino-C
1-6
alkyl-, C
1-6
alkyl-C(═O)—NH—C
1-6
alkyl-, mono- or di(C
1-6
alkyl)amino-C(═O)—C
1-6
alkyl-, phenyl-C
1-6
alkyl-, or Het
4
-C
1-6
alkyl-;
Q is phenyl, pyridyl, benzofuranyl, 2,3-dihydro-benzofuranyl, pyrazolyl, isoxazolyl or indazolyl wherein each of said ring systems is optionally being substituted with up to three substituents each independently selected from halo, cyano, C
1-6
alkyl, C
1-6
alkyl-O—, C
1-6
alkylthio, Ar or polyhaloC
1-6
alkyl;
L is phenyl, pyridyl, pyrimidazolyl, 8-Azapyrimidazolyl, pyridazinyl, imidazothiazolyl or furanyl wherein each of said ring systems may optionally be substituted with one or two or more substituents, each substituent independently being selected from halo, hydroxy, amino, cyano, C
1-6
alkyl or C
1-6
alkyl-O—;
Het
1
represents morpholinyl; pyrazolyl or imidazolyl;
Het
4
represents morpholinyl, pyrazolyl or imidazolyl;
Ar represents phenyl optionally substituted with halo, C
1-6
alkyl, C
1-6
alkyl-O— or polyhaloC
1-6
alkyl; for the manufacture of a medicament for the prevention or the treatment or prophylaxis of psychotic disorders, intellectual impairment disorders or diseases or conditions in which modulation of the α7 nicotinic receptor is beneficial.
这项发明涉及使用式(I)中的化合物,其中N-
氧化物是药用可接受的加合盐,季
铵基和其立体化异构形式,其中Z为
氢、卤素、C1-6烷基、Het1、HO—C1-6烷基、
氰基-C1-6烷基、
氨基-C(═O)—C1-6烷基、甲酰
氨基-C1-6烷基、C1-6烷基-C(═O)—NH—C1-6烷基、单烷基或二烷基胺基-C(═O)—C1-6烷基、
苯基-C1-6烷基或Het4-C1-6烷基;Q为
苯基、
吡啶基、
苯并呋喃基、
2,3-二氢苯并呋喃基、
吡唑基、
异噁唑基或
吲唑基,其中每个环系统可选地被取代,每个取代基可独立地选择自卤素、
氰基、C1-6烷基、C1-6烷基-O—、C1-6烷基
硫醚、Ar或多卤代C1-6烷基;L为
苯基、
吡啶基、
嘧啶嗪基、8-
吡啉嗪基、
吡啶嗪基、
咪唑噻唑基或
呋喃基,其中每个环系统可选地被取代,每个取代基可独立地选择自卤素、羟基、
氨基、
氰基、C1-6烷基或C1-6烷基-O—;Het1代表
吗啉基;
吡唑基或
咪唑基;Het4代表
吗啉基、
吡唑基或
咪唑基;Ar代表
苯基,可选地被卤素、C1-6烷基、C1-6烷基-O—或多卤代C1-6烷基取代;用于制备一种用于预防或治疗或预防精神障碍、智力障碍或调节α7
尼古丁受体有益的疾病或情况的药物。